Aktienanalyse zu Autolus Therapeutics PLC (AUTL)AUTLAutolus Therapeutics PLC

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Autolus Therapeutics PLC (AUTL) is a good buy right now due to its significant revenue growth, with Q2 product sales reaching $45.69 million, a 119% year-over-year increase. Additionally, the company has improved its gross margin to 57.61% in Q2 2026, up from just 13.92% in Q1 2026, indicating strong operational efficiency. The main risk is the ongoing net losses, which were $39.11 million in Q2 2026, but the raised revenue guidance for the year to between $140 million and $150 million suggests a positive outlook.

2 analysts cover AUTL: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.18.